About the topic
In 2020, 2.7 million people in the European Union were diagnosed with cancer, and another 1.3 million lost their lives to it. Today, Europe accounts for a tenth of the world’s population, but a quarter of the global cancer cases. Lives lost to cancer in the EU are set to increase by more than 24% by 2035, making it the leading cause of death in the EU.
Cancer prevention and screening (early detection) offer the best chance of a contribution to beat cancer and save lives. As of 2020, 25 EU countries had introduced population-based screening in their National Cancer Control Plans programmes for breast cancer, 22 countries have done the same for cervical cancer and 20 for colorectal cancer.
In 2022, the Commission will make a proposal to update the 2003 Council Recommendation on cancer screening to ensure the latest available scientific evidence is reflected. One of the aims will be to consider the extension of cancer screening beyond breast, colorectal and cervical cancer to include prostate, lung and gastric cancer, as well as other cancers if supported by scientific evidence.
The proposal will be informed by advice from the European Commission’s Group of Chief Scientific Advisors which was adopted on 2 March 2022
Advice and related documents
Scientific Opinion: Cancer screening in Europe (March 2022) informed by SAPEA Evidence Review Report (March 2022)
Executive Summary: Cancer screening in Europe (March 2022)
One page Summary: Cancer screening in Europe (March 2022)
Scoping paper – Cancer screening in Europe (April 2021)
- News article
Some cancer screening changes are relatively straightforward and should be cost effective
The EU has just announced recommendations on a new approach of ‘screening more and screening better’ to combat cancer cases. In this exclusive interview with Horizon Magazine, Prof Rebecca Fitzgerald.
- News article
Horizon Magazine: Better cancer screening proves a game-changer
Don’t underestimate the lifesaving ability of cancer screening. For lung cancer and prostate cancer, screening is recommended across the EU, based on the most up-to-date evidence.